RT Journal Article
SR Electronic
T1 Evaluation of the Roche Elecsys Anti-SARS-CoV-2 Assay
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.28.20142232
DO 10.1101/2020.06.28.20142232
A1 CS Lau
A1 SP Hoo
A1 SF Yew
A1 SK Ong
A1 LT Lum
A1 PY Heng
A1 JG Tan
A1 MS Wong
A1 TC Aw
YR 2020
UL http://medrxiv.org/content/early/2020/06/29/2020.06.28.20142232.abstract
AB Background Little is known about the performance of the Roche novel severe acute respiratory syndrome coronavirus 2 antibody (anti-SARS-CoV-2) assay. We provide an extensive evaluation of this fully automated assay on the Cobas e801/e602 immunoassay analysers.Methods We assessed the linearity, precision, and throughput of the Roche anti-SARS-CoV-2 assay. Sensitivity was calculated from 349 SARS-CoV-2 polymerase chain reaction (PCR) positive samples; specificity was determined from 714 coronavirus disease 2019 (COVID-19)-naive samples. We examined cross-reactivity against other antibody positive samples (syphilis, RF, ANA, ds-DNA, influenza, dengue, HBV, HCV) and the anti-SARS-CoV-2 kinetics.Results The assay cut-off index (COI) was linear up to 90.7. The inter-assay precision was 2.9% for a negative control (COI=0.1) and 5.1% for a positive control (COI=3.0). Assay time is 18min and results are available 1 minute later; throughput for 300 samples was 76 minutes. No cross-reactivity was observed with other antibody positive samples; specificity was 100%. The assay has a sensitivity of 97.1% 14 days after PCR positivity (POS) and 100% at ≥21 days POS; 48.2% of cases had anti-SARS-CoV-2 within 6 days POS. In 11 subjects in whom serum was available prior to a positive antibody signal (COI ≥1.0) the interval between the last negative and first positive COI (time to “sero-conversion”) on average is 3 days (range 1-6 days) and 4 more days (range 1-7) for the anti-SARS-CoV-2 to plateau.Conclusion The Roche anti-SARS-CoV-2 assay shows excellent performance with minimal cross-reactivity from other viral and confounding antibodies. Antibody development and sero-conversion appears quite early.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNAAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CHANGI GENERAL HOSPITAL INSTITUTIONAL REVIEW BOARDAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNASARS-CoV-2Novel severe acute respiratory syndrome coronavirus 2COVID-19Coronavirus disease 2019Anti-SARS-CoV-2SARS-CoV-2 antibodyFDAFood and Drug AdministrationHCVHepatitis CHBVHepatitis BRFRheumatoid factorHCWsHealth care workersCOICut-off indexPCRPolymerase chain reactionCVInter-assay precisionPPAPositive percentage agreementNPANegative percentage agreementPOSPost positive PCRPPVPositive predictive valueNPVNegative predictive valueCDCCenters for Disease Control and PreventionPPEPersonal protective equipmentANAanti-nuclear antibodyAnti-ds-DNAdouble-stranded DNA antibody